Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.

被引：0
|
作者：
Seedor, Rino S.
Orloff, Marlana M.
Sharpe-Mills, Erin
Hulse, Liam
Shelat, Reshma
Shimada, Ayako
Chervoneva, Inna
Shields, Carol L.
Shields, Jerry A.
Mastrangelo, Michael J.
Sato, Takami
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA
[2] Wills Eye Hosp & Res Inst, Oncol Serv, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9586
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.
    Sato, Takami
    Orloff, Marlana M.
    Valsecchi, Matias Emanuel
    Shimada, Ayako
    Chervoneva, Inna
    Sharpe-Mills, Erin
    Klose, Haley
    Norcini, Jessica
    Belinsky, Jill
    Sato, Shingo
    Hulse, Liam
    Shields, Carol L.
    Shields, Jerry A.
    Mastrangelo, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study
    Valsecchi, Matias Emanuel
    Shockley, Nancy
    Summers, Deborah
    Shields, Carol L.
    Shields, Jerry A.
    Mastrangelo, Michael J.
    Sato, Takami
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Quality-of-life measurement in high-risk patients with uveal melanoma receiving adjuvant sunitinib or valproic acid
    Maniraho, Regine Nshimiyimana
    Keith, Scott W.
    Orloff, Marlana M.
    Seedor, Rino S.
    Downie, Leah
    Hulse, Liam
    Sato, Shingo
    Sharpe-Mills, Erin
    Sato, Takami
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma Comparison with Institutional Controls
    Valsecchi, Matias E.
    Orloff, Marlana
    Sato, Rino
    Chervoneva, Inna
    Shields, Carol L.
    Shields, Jerry A.
    Mastrangelo, Michael J.
    Sato, Takami
    OPHTHALMOLOGY, 2018, 125 (02) : 210 - 217
  • [5] A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.
    Marshall, Ernest
    Coupland, Sarah
    Corrie, Philippa
    Damato, Bertil
    Danson, Sarah
    Dobson, Lisa
    Evans, T. R. Jeffry
    Goodman, Andrew
    Kalirai, Helen
    Jones, Sarah
    Kumar, Satish
    Larkin, James M. G.
    Lorigan, Paul
    Nicholson, Steve
    Ottensmeier, Christian
    Silcocks, Paul
    Steven, Neil
    Tudur-Smith, Catrin
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients
    Voelter, Verena
    Schalenbourg, Ann
    Pampallona, Sandro
    Peters, Solange
    Halkic, Nermin
    Denys, Alban
    Goitein, Gudrun
    Zografos, Leonidas
    Leyvraz, Serge
    MELANOMA RESEARCH, 2008, 18 (03) : 220 - 224
  • [7] Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309)
    Rapisuwon, Suthee
    Carvajal, Richard D.
    Ansstas, George
    Tsai, Katy K.
    Hernandez-Aya, Leonel Fernando
    Khan, Shaheer
    Chandra, Sunandana
    Harbour, J. William
    Sosman, Jeffrey A.
    Daud, Adil
    Decatur, Christina
    Ozisik, Deniz
    Tan, Ming Tony
    Atkins, Michael B.
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Follow-up study in high-risk uveal melanoma patients
    Mariani, P.
    Servois, V.
    Piperno-Neumann, S.
    Couturier, J.
    Plancher, C.
    Levy-Gabriel, C.
    Le Rouic, L. Lumbroso
    Salmon, R.
    Asselain, B.
    Desjardins, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 582 - 582
  • [9] Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma
    Decoster, Lore
    Broek, Isabelle Vande
    Neyns, Bart
    Majois, Francoise
    Baurain, Jean Francois
    Rottey, Sylvie
    Rorive, Andree
    Anckaert, Ellen
    De Mey, Johan
    De Brakeleer, Sylvia
    De Greve, Jacques
    ANTICANCER RESEARCH, 2015, 35 (12) : 6893 - 6899
  • [10] Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
    George, Daniel J.
    Martini, Jean-Francois
    Staehler, Michael
    Motzer, Robert J.
    Magheli, Ahmed
    Donskov, Frede
    Escudier, Bernard
    Li, Sherry
    Casey, Michelle
    Valota, Olga
    Laguerre, Brigitte
    Pantuck, Allan J.
    Pandha, Hardev S.
    Patel, Anup
    Lechuga, Maria
    Ravaud, Alain
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1165 - 1173
12345